BIO Asia–Taiwan 2025 亞洲生技大會

Pushing the Boundaries of 

Antibody Science 

Join us for this dynamic session spotlighting the cutting edge of antibody derivative innovation. This forum will showcase how antibody-based technologies are being reimagined for broader, more precise therapeutic applications across autoimmune disorders, oncology, and neurodegenerative diseases.

The session opens with remarks from Lee-Cheng Liu, Founder, Chairman & President of EirGenix, Inc., and unfolds with breakthrough presentations, including:

• Yen-Ming Hsu, CEO of AB Biosciences, on Oligomeric-Fc as a replacement for plasma-derived IVIG in autoimmune treatment

• David Huang, Senior Director at OBI Pharma, introducing GlycOBI®—a novel multi-platform ADC technology for site-specific and dual-payload conjugates

• Oshra Betzer, COO of Nanocarry Therapeutics, unveiling a nano-platform that enables antibody therapies to cross the blood-brain barrier

• Ming-Tang Chen, Senior Director at PharmaEssentia Innovation Research Center, presenting the promise of immunocytokines for targeted immune modulation

• Jeng Her, CEO of AP Biosciences, sharing insights into T-cube, a non-CD3-based T-cell engager platform designed with a superior safety profile

The session culminates in a thought-provoking panel discussion, co-moderated by Lee-Cheng Liu and Heidi Wang, CEO of OBI Pharma, with panelists representing top biotech firms across Asia, Europe, and the U.S., including Oncomatryx, Formosa Laboratories, Nanocarry, PharmaEssentia, AB Biosciences, and AP Biosciences.

This is a must-attend for anyone interested in the future of biologics, bispecific antibodies, ADCs, and immune modulation.

Explore how cross-disciplinary platforms are reshaping the possibilities of antibody-based therapeutics.

Register Now & Save $100
Deadline: July 15